reports
- Carole Braudeau
- Carole Braudeau
- Maxime Kogge
- Maxime Kogge
- Oliver Metzger
- ABGSC Healthcare Research
- Morten Larsen
- Cor Kluis
- Roy Külter
- Steven Boumans
Coloplast A/S - Regnskabsmeddelelse, 9M 2024/25
Coloplast A/S - Regnskabsmeddelelse, 9M 2024/25 2024/25 Delårsrapport, 9M 2024/25 1. oktober 2024 - 30. juni 2025 Coloplast leverede en organisk vækst på 7% og en overskudsgrad1 på 28% i 3. kvartal. Den rapporterede omsætning i danske kroner steg 1%, negativt påvirket af valutaudviklingen samt frasalget af hudplejeforretningen. Den organiske vækst pr. forretningsområde: Stomi 6%, Kontinens 8%, Stemme og Respiratorisk Pleje 9%, Avanceret Sårpleje 4% og Urologi 4%.Væksten i Stomi var drevet af et bredt baseret bidrag fra alle regioner, bortset fra Kina, som leverede en lav-encifret v...
Coloplast A/S - Interim Financial Report, 9M 2024/25
Coloplast A/S - Interim Financial Report, 9M 2024/25 2024/25 Interim financial results, 9M 2024/25 1 October 2024 - 30 June 2025 Coloplast delivered organic growth of 7% and an EBIT margin1 of 28% in Q3. Reported revenue in DKK grew 1% with negative impact from currencies and the Skin Care divestment. Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 4% and Interventional Urology 4%.Growth in Ostomy Care was driven by broad-based contribution across regions, except for China which delivered low-single digit gro...
Coloplast A/S - Selskabsmeddelelse nr. 05/2025 - Coloplast ændrer i le...
Coloplast A/S - Selskabsmeddelelse nr. 05/2025 - Coloplast ændrer i ledelsesteamet Coloplast ændrer i ledelsesteamet Coloplasts bestyrelse laver ændringer til ledelsesteamet (ELT) for at understøtte en succesfuld eksekvering af ny strategi. I løbet af de seneste måneder har seniorledere fra hele Coloplast arbejdet sammen om at færdiggøre Coloplasts nye strategi, som vil blive lanceret internt og eksternt i begyndelsen af september efter bestyrelsens godkendelse. "Vores nye strategi er centreret omkring vores kunder. Vi vil skabe og levere den bedste kundeoplevelse for vores brugere, pati...
Coloplast A/S - Announcement no. 05/2025 - Coloplast announces changes...
Coloplast A/S - Announcement no. 05/2025 - Coloplast announces changes to Executive Leadership Team Coloplast announces changes to Executive Leadership Team The Coloplast Board of Directors are making changes to the Executive Leadership Team (ELT) to support the successful execution of the new Coloplast Group strategy. Over the last couple of months, senior leaders from across the Coloplast Group have worked together to finalise the new Coloplast Group strategy, which will be communicated internally and externally in early September following approval by the Board of Directors. “Our new ...
- ABGSC Healthcare Research
- Morten Larsen
- Cor Kluis
- Julian Dobrovolschi
- Cor Kluis
- Julian Dobrovolschi
- Cor Kluis
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Lynn Hautekeete
- Michiel Declercq
- Thomas Couvreur
- Wim Lewi
Coloplast A/S - 9M 2024/25 Earnings Release - Invitation to conference...
Coloplast A/S - 9M 2024/25 Earnings Release - Invitation to conference call on 19 August 2025 at 11.00am CEST Tuesday, 19 August 2025 at 11.00 - 12.00h CESTIn connection with the publication of Coloplast’s interim financial results for 9M 2024/25, to be released same day in the morning around 07.30h CEST, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.The webcast of the conference call will be available d...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.